Health care stocks were mixed pre-bell Thursday, with The Health Care Select Sector SPDR Fund (XLV) marginally lower and the iShares Biotechnology ETF (IBB) up 0.5%.
UnitedHealth Group (UNH) is facing a criminal investigation by the US Department of Justice over possible Medicare fraud tied to its Medicare Advantage operations, The Wall Street Journal reported, citing people familiar with the matter. The company's shares were down past 8% premarket.
Biohaven (BHVN) stock was more than 11% lower after the company said Wednesday that the US Food and Drug Administration's Office of Neuroscience is extending the Prescription Drug User Fee Act, or PDUFA, date for troriluzole's new drug application for the treatment of spinocerebellar ataxia by three months.
Mesoblast (MESO) shares were up over 7% after the company said overnight it received seven years of orphan drug exclusivity from the US Food and Drug Administration for Ryoncil, a treatment approved for steroid-refractory acute graft versus host disease in children aged two months and older.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。